Fact based stock research
Assertio Therapeutics (NasdaqGS:ASRT)

US04545L1070

Assertio Therapeutics stock research in summary

Assertio Therapeutics shares have a market-typical stock price level. While they are good value, they show below average growth, and are riskily financed. We recommend evaluating whether the future of the company Assertio Therapeutics is typical for this industry which the market average price level of the shares suggests. If you believe that the future of the company is above average, that could be an argument for buying the shares and vice versa.

Latest Obermatt Ranks


Value Rank	60
Growth Rank	2
Safety Rank	1
Combined Rank	5

Country	USA
Industry	Pharmaceuticals
Index	NASDAQ, D.J. US Pharmaceutical
Size class	Small

January 17, 2020. Stock data may be delayed. Login to get the most recent research.

Add to Watchlist

Filter Similar Stocks

Similar Top 10

☀ Achievements

Top 10 Stock

Google: Assertio Therapeutics

News	Videos
Wikipedia about Assertio Therapeutics	Management
Employee Satisfaction	Customer Satisfaction

Research History: Assertio Therapeutics

RESEARCH HISTORY	2017	2018	2019	2020
VALUE
VALUE	44	34	60	60
GROWTH
GROWTH	2	33	1	2
SAFETY
SAFETY	7	29	14	1
COMBINED
COMBINED	1	33	1	5

Last update of Combined Rank: 17-Jan-2020. Financial reporting date used for calculating ranks: 30-Sep-2019. Stock research history is based on the Obermatt Method. The higher the rank, the better Assertio Therapeutics is in the corresponding investment strategy.

Value Metrics in Detail

VALUE METRICS	2017	2018	2019	2020
PRICE VS. REVENUES (P/S)
PRICE VS. REVENUES (P/S)	93	91	100	98
PRICE VS. PROFITS (P/E)
PRICE VS. PROFITS (P/E)	8	10	29	29
PRICE VS. CAPITAL (Market-to-Book)
PRICE VS. CAPITAL (Market-to-Book)	82	84	94	96
DIVIDEND YIELD
DIVIDEND YIELD	1	1	1	1
CONSOLIDATED RANK: VALUE
CONSOLIDATED RANK: VALUE	44	34	60	60

Last update of Value Rank: 17-Jan-2020. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Assertio Therapeutics; except for dividend yield where the rank is higher, the higher the yield.

Growth Metrics in Detail

GROWTH METRICS	2017	2018	2019	2020
REVENUE GROWTH
REVENUE GROWTH	4	15	1	7
PROFIT GROWTH
PROFIT GROWTH	1	78	38	19
STOCK RETURNS
STOCK RETURNS	10	20	8	4
CONSOLIDATED RANK: GROWTH
CONSOLIDATED RANK: GROWTH	2	33	1	2

Last update of Growth Rank: 30-Sep-2019. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Assertio Therapeutics.

Safety Metrics in Detail

SAFETY METRICS	2017	2018	2019	2020
LEVERAGE
LEVERAGE	8	10	1	2
REFINANCING
REFINANCING	1	10	1	1
LIQUIDITY
LIQUIDITY	23	64	64	35
CONSOLIDATED RANK: SAFETY
CONSOLIDATED RANK: SAFETY	7	29	14	1

Last update of Safety Rank: 10-Jan-2020. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Assertio Therapeutics and the more cash is available to service its debt.

Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Assertio Therapeutics from January 17, 2020.

We invest in our stock tips ourselves and openly publish the returns of our portfolio. That's how much we believe in our stock research. Subscribe to the top 10 stocks for 100 markets conveniently by e-mail.